Vertex Pharmaceuticals’ investigational allogeneic stem cell therapy for type 1 diabetes has demonstrated promising clinical results, enabling 10 out of 12 participants to discontinue insulin treatment after one year. The therapy, based on lab-grown islet cells called zimislecel (VX-880), sustains endogenous insulin production and stable blood glucose levels, with no severe hypoglycemic events reported. Data presented at the ADA meeting and published in NEJM mark a significant advance in cell replacement therapies for diabetes management.